Document Detail


Changing costs and the impact on RSV prophylaxis.
MedLine Citation:
PMID:  21087075     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
OBJECTIVE: Acquisition costs of palivizumab have increased in Canada since 2007. This analysis aims to re-evaluate the cost effectiveness of palivizumab in Canada for premature infants born between 32 and 35 weeks' gestational age using updated 2010 healthcare costs compared to those used in a 2007 decision analytic model.
METHODS: New costs (CAN$) were acquired from the same Health Canada and Ontario Ministry of Health sources that were utilized in the previously published 2007 model. Palivizumab prices were acquired from Abbott Laboratories Ltd., current as of August 2010.
RESULTS: Incremental cost-effectiveness ratios (ICERs) rose by $742, going from $30,618/QALY to $31,360/QALY. ICER changes increased from a range of $801,297 to $820,701 for infants with zero risk factors to a decrease from $808 to $192 for infants with four or more risk factors.
CONCLUSIONS: Palivizumab ICERs remained fairly stable from 2007 to 2010. The original recommendation stating that palivizumab is cost effective in infants born between 32 and 35 weeks' GA with two or more risk factors, or who are at moderate-to-high risk based on a risk assessment model, does not change. Analyses founded on evolving country-specific variables are needed in order to accurately reassess the cost effectiveness of interventions as costs change worldwide.
LIMITATIONS: There are a limited number of publications reporting mortality in premature Canadian infants with RSV as a primary outcome. In addition, conclusions drawn from this analysis are country-specific and limited to premature infants dwelling in Canada.
Authors:
Kelly A Smart; Bosco A Paes; Krista L Lanctôt
Related Documents :
21127005 - Mothers, places and small for gestational age births: a cohort study.
11133075 - Treatment of experimental allergic encephalomyelitis (eae) by a rationally designed cyc...
11234565 - Electromyographic characteristics at the onset of independent walking in infancy.
6668635 - Assessment of the consequences of the house-spraying of malathion on the interruption o...
12969205 - Delta-f508 cystic fibrosis mutation is not linked to intussusception: implications for ...
7797285 - Sigmoido-rectal intussusception.
Publication Detail:
Type:  Journal Article     Date:  2010-11-18
Journal Detail:
Title:  Journal of medical economics     Volume:  13     ISSN:  1941-837X     ISO Abbreviation:  J Med Econ     Publication Date:  2010  
Date Detail:
Created Date:  2010-12-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9892255     Medline TA:  J Med Econ     Country:  England    
Other Details:
Languages:  eng     Pagination:  705-8     Citation Subset:  IM    
Affiliation:
Medical Outcomes and Research in Economics Group, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistent asthma defined using HEDIS versus survey criteria.
Next Document:  Topoisomerases and site-specific recombinases: similarities in structure and mechanism.